Explore

Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership
Trendline Trendline
Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss
Trendline Trendline
Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome
Trendline Trendline
ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer